Showing results (371-380 of 7,002) with videos related to

Sort By:
Pageof 701
Lung Cancer (Amsterdam, Netherlands)|August 24, 2025
Changes in use of radiotherapy for lung cancer - A Norwegian population-based study from 2000 until 2020Gustav Graabak, Tarje Onsøien Halvorsen, Bjørn Henning Grønberg, et al.
Lung Cancer (Amsterdam, Netherlands)|June 24, 2015
Silencing of miR-137 by aberrant promoter hypermethylation in surgically resected lung cancerNahyeon Kang, Su Yeon Choi, Young Kyoon Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|June 28, 2015
The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysisFei Zhou, Tao Jiang, Wanrong Ma, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2025
Prediction recurrence in stage I epidermal growth factor receptor-mutated non-small cell lung cancer using multi-modal dataAkiko Tateishi, Hidehito Horinouchi, Nobuji Kouno, et al.
Lung Cancer (Amsterdam, Netherlands)|August 21, 2021
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinomaColin R Lindsay, Marina C Garassino, Ernest Nadal, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2021
Mutational landscape of primary pulmonary salivary gland-type tumors through targeted next-generation sequencingFang Wang, Shao-Yan Xi, Wen-Wen Hao, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2021
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)Misako Nagasaka, Mohammad Fahad B Asad, Mohammed Najeeb Al Hallak, et al.
Lung Cancer (Amsterdam, Netherlands)|August 1, 2021
Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitorsKiyotaka Yoh, Shingo Matsumoto, Naoki Furuya, et al.
Lung Cancer (Amsterdam, Netherlands)|August 16, 2022
Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironmentNeal Akhave, Jiexin Zhang, Erin Bayley, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2021
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and CanadaDidier Debieuvre, Rosalyn A Juergens, Bernard Asselain, et al.
Pageof 701